Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700071 | 1.00 | PDE10A (0.55) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL9700054 | 0.96 | PDE10A (0.52) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL7374930 | 0.87 | PDE10A (0.53) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL27310627 | 0.85 | PDE10A (0.46) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL9199906 | 0.81 | PDE10A (0.57) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL7378515 | 0.81 | TGFBR1 (0.65) | PDE10ATGFBR1SMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL9297972 | 0.81 | PDE10A (0.57) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL7343693 | 0.81 | TGFBR1 (0.65) | PDE10ATGFBR1SMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL9202891 | 0.81 | PDE10A (0.55) | PDE10ATGFBR1ATMSMN1; SMN2NPC1 | |
| SCHEMBL9752587 | 0.80 | PDE10A (0.60) | PDE10ATGFBR1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091960-A1 | BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-18 | — | — | EP | claimed |
| WO-2000000491-A1 | BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-06 | — | — | WO | claimed |
| EP-0306300-B1 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORP (US) | 1995-05-03 | — | — | EP | claimed |
| EP-0561898-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-29 | — | — | EP | claimed |
| WO-1992010499-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-06-25 | — | — | WO | claimed |
| EP-0364204-A1 | Pyrrolo[1,2-a]imidazole and imidazo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-18 | — | — | EP | claimed |
| EP-0306300-A2 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-08 | — | — | EP | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0889726-B1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-0411754-A2 | Medicament for the inhibition of interleukin-1 or tumor necrosis factor production by monocytes and/or macrophages | SMITHKLINE BEECHAM CORPORATION (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1991000092-A1 | INHIBITION OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR PRODUCTION BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-01-10 | — | — | WO | disclosed |
| WO-1990015534-A1 | MONOKINE ACTIVITY INTERFERENCE | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-27 | — | — | WO | disclosed |
| EP-0403251-A2 | Monokine activity interference | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| WO-1990003789-A1 | PYRROLO[1,2-a]IMIDAZOLE AND IMIDAZO[1,2-a]PYRIDINE DERIVATIVES AND THEIR USE AS 5-LYPOXYGENASE PATHWAY INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-19 | — | — | WO | disclosed |
| EP-0364204-A1 | Pyrrolo[1,2-a]imidazole and imidazo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-18 | — | — | EP | disclosed |
| EP-0306300-A2 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | PDE10A 2226/4885TGFBR1 4330/4885ATM 4845/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | PDE10A 2226/4885TGFBR1 4330/4885ATM 4845/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | PDE10A 2251/4885TGFBR1 3474/4885ATM 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.